1.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2008-0503, NCT00887068
|
|
3.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AZA-MDS-003, 2012-002471-34, NCT01566695
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 55 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-486-AML-001, 2012-003457-28, NCT01757535
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0737, NCT01787487
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00220, J0658, CDR0000504083, U01CA070095, JHOC-J0658, 7759, NCT00387465
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: Other
Protocol IDs: HCI53993, NCT00748553
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 090516, NCT00766116
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EPROST-20061143, SCCC-2006080, WIRB-20070344, SCCC-EPROST-20061143, PHARMION-SCCC-2006080, NCT00503984
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0907010513, NCT01004991
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-1816 / 201101749, NCT01016600
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 2009-0467, NCT01038635
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI
Protocol IDs: CASE1908, NCI-2009-01285, NCT01093573
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0912010795, NCT01120834
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE1A09, NCI-2010-01139, NCT01155583
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-0625, NCT01193517
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0374, NCT01202877
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-AZA-IDA-09, NCT01305135
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-Aza-ceplene, NCT01324960
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 90
Sponsor: Other
Protocol IDs: Allo-Relapse-2011, NCT01369368
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2011-0254, NCT01460498
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GFM-AZA intensif, NCT01305460
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: RG_11-187, NCT01617226
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2011-0188, NCT01636609
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 201303012, NCT01747499
|
Mobile | Español